Dysphagia Knowledge Hub — 吞嚥困難知識庫

ALS (Motor Neuron Disease) and Dysphagia: Clinical Management Across Disease Stages

Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND) in some regions, is a progressive neurodegenerative disease that affects upper and lower motor neurons. Dysphagia is nearly universal in ALS — ~30% of patients present with bulbar symptoms as the first sign, and >80% develop dysphagia by late disease. This article provides a clinical reference for SLPs, physiotherapists, dietitians, and family caregivers managing dysphagia in ALS.

1. Pathophysiology of ALS Dysphagia

1.1 The motor pathway affected

ALS damages both:

This produces a mixed bulbar syndrome:

Site affected Symptom
Trigeminal (V) Jaw weakness, chewing difficulty
Facial (VII) Lip seal failure, drooling
Glossopharyngeal (IX) Sensory loss posterior tongue
Vagus (X) Pharyngeal paralysis, reflux
Hypoglossal (XII) Tongue weakness, fasciculations

1.2 Upper vs Lower Motor Neuron patterns

1.3 Timeline of swallowing deterioration

2. Early Detection and Assessment

2.1 Screening tools

ALSFRS-R Bulbar Subscore (part of ALS Functional Rating Scale-Revised):

Score Speech Salivation Swallowing
4 Normal Normal Normal
3 Detectable abnormality Slight excess Early eating problems
2 Intelligible with repeats Moderate excess Consistency changes needed
1 Combines non-vocal Severe excess Supplemental tube feeding
0 Loss of speech Marked drooling NPO

Bulbar subscore < 10/12 suggests need for urgent dysphagia evaluation.

2.2 CNS-BFS (Center for Neurologic Study-Bulbar Function Scale)

2.3 Instrumental assessment

Recommendation: Baseline instrumental assessment at diagnosis + repeat every 3 months or with symptom change.

2.4 IOPI (Iowa Oral Performance Instrument)

3. Disease-Stage Management Framework

3.1 Stage 1: Mild bulbar involvement (ALSFRS-R bulbar 10-12)

Presentation: Occasional choking on liquids, minor speech slurring, normal nutrition.

Management:

3.2 Stage 2: Moderate bulbar involvement (ALSFRS-R bulbar 7-9)

Presentation: Daily choking, slower eating (>45 min), weight loss >5%, fatigue during meals.

Management:

3.3 Stage 3: Severe bulbar involvement (ALSFRS-R bulbar 4-6)

Presentation: Near-total reliance on pureed diet, frequent aspiration events, sialorrhea, communication very difficult.

Management:

3.4 Stage 4: End-stage

Presentation: Cannot protect airway, NIV dependent, communication by AAC or eye-gaze device.

Management:

4. PEG Tube Decision: Timing is Everything

4.1 Why PEG in ALS?

4.2 When to place PEG

Indications:

Critical timing window:

4.3 PEG placement methods in ALS

4.4 Post-PEG considerations

5. Saliva Management in Detail

Sialorrhea (excessive drooling) in ALS is caused by reduced spontaneous swallowing, not increased saliva production. Management targets:

  1. Reducing saliva volume
  2. Improving swallow frequency
  3. Absorbing excess saliva

5.1 Pharmacological

Drug Dose Mechanism Side effects
Glycopyrrolate 1-2 mg po TID Anticholinergic (peripheral) Less CNS effects, constipation
Amitriptyline 10-25 mg qhs Anticholinergic + serotonergic Sedation, cognitive effects
Scopolamine patch 1.5 mg q72h Anticholinergic Confusion, urinary retention
Atropine 1% drops 1-2 drops sublingual TID Local anticholinergic Less systemic effect

5.2 Procedural

5.3 Mechanical

6. NIV (Non-Invasive Ventilation) and Dysphagia Interaction

NIV (typically BiPAP) is used in ALS to support ventilation when respiratory muscles weaken. It creates a dysphagia management dilemma:

6.1 NIV titration and mealtimes

7. Aspiration Pneumonia: The Common Endpoint

Aspiration pneumonia is the leading cause of death in ALS alongside respiratory failure.

7.1 Prevention

7.2 Treatment decisions

Aspiration pneumonia treatment in advanced ALS requires:

8. Speech-Language Pathology Role Throughout Disease

8.1 At diagnosis

8.2 Mid-disease

8.3 Late-disease

9. Family Caregiver Support

9.1 Training priorities

9.2 Caregiver burden

10. End-of-Life Dysphagia Considerations

10.1 Comfort feeding only

When patient enters hospice/end-of-life phase:

10.2 Dyspnea management

10.3 Sialorrhea at end of life

11. Key Clinical Pearls

  1. PEG early, not late — FVC > 50% is the sweet spot
  2. Do not over-exercise swallowing muscles — may accelerate atrophy
  3. Hypermetabolism is real — ALS patients need 10-15% more calories than predicted
  4. Saliva problem ≠ more saliva — it is less swallowing
  5. NIV + oral eating is impossible together — plan accordingly
  6. Oral hygiene is anti-aspiration therapy — 40-50% reduction in pneumonia
  7. Advance Care Planning must happen while patient can still communicate
  8. Palliative care is not giving up — it is quality of life optimization
  9. Family training is as important as patient care
  10. SLP role continues to death — AAC, comfort feeding, family support

12. Summary

ALS dysphagia is predictable in trajectory but highly individual in timing. The clinical management framework rests on three pillars:

  1. Early assessment and longitudinal monitoring (quarterly ALSFRS-R + instrumental)
  2. Stage-matched intervention (postural → diet modification → PEG → comfort care)
  3. Integrated multidisciplinary team (neurology, SLP, dietitian, respiratory, palliative)

The PEG decision at FVC > 50% is the single most important timing call in ALS dysphagia care. Miss that window and subsequent interventions become compromised.

Above all, ALS care requires acknowledging that dysphagia is progressive and terminal — the goal is not cure, but preservation of dignity, safety, and quality of life through the disease course.

This clinical reference is based on AAN Practice Parameters (Miller et al. 2009), EFNS guidelines (Andersen et al. 2012), Cochrane reviews, and recent SLP consensus statements. Always individualize care to patient goals and preferences.

This site is open source. Improve this page.